SCHEMBL607992

SCHEMBL607992

Brc1ccc2c(c1)c1cc(Br)ccc1n2CC(CN1CCNCC1)NCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BAX Q07812 2/20 0.60
MAPT P10636 3/20 0.58
TP53 P04637 1/20 0.58
CYP3A4 P08684 1/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58
RAD52 P43351 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
DNM1 Q05193 7/20 0.43
DNMT1 P26358 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
HTT P42858 2/20 0.38
IDO1 P14902 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CXCR4 P61073 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5028685 0.84 KMT2A (0.46) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL7649594 0.80 KMT2A (0.44) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL605851 0.78 CHRM2 (0.43) RAD52KMT2AMEN1DNMT1HTT
SCHEMBL7654426 0.77 BAX (0.50) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5026838 0.77 KMT2A (0.39) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5024368 0.75 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL607745 0.75 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL607771 0.75 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL609455 0.75 BAX (1.00) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5024320 0.75 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD BAX 2/4885MAPT 1085/4885TP53 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.